scholarly journals Combination therapy using molecular-targeted drugs modulates tumor microenvironment and impairs tumor growth in renal cell carcinoma

2017 ◽  
Vol 6 (10) ◽  
pp. 2308-2320 ◽  
Author(s):  
Hiroyuki Kitano ◽  
Yasuhiko Kitadai ◽  
Jun Teishima ◽  
Ryo Yuge ◽  
Shunsuke Shinmei ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Tumor Microenvironment ◽  
Combination Therapy ◽  
Tumor Growth ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Targeted Drugs

scholarly journals Systemic Injection of Oncolytic Vaccinia Virus Suppresses Primary Tumor Growth and Lung Metastasis in Metastatic Renal Cell Carcinoma by Remodeling Tumor Microenvironment

Biomedicines ◽  
2022 ◽  
Vol 10 (1) ◽  
pp. 173
Author(s):  
Jee Soo Park ◽  
Myung Eun Lee ◽  
Won Sik Jang ◽  
Jongchan Kim ◽  
Se Mi Park ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Tumor Microenvironment ◽  
Tumor Growth ◽  
Cell Carcinoma ◽  
Primary Tumor ◽  
Renal Cell ◽  
Early Stage ◽  
Advanced Stage ◽  
Primary Tumor Growth ◽  
Systemic Injection

Immune checkpoint inhibitors and tyrosine kinase inhibitors are the first-line treatment for metastatic renal cell carcinoma (mRCC), but their benefits are limited to specific patient subsets. Here, we aimed to evaluate the therapeutic efficacy of JX-594 (pexastimogene devacirepvec, Pexa-vec) monotherapy by systemic injection in comparison with sunitinib monotherapy in metastatic orthotopic RCC murine models. Two highly metastatic orthotopic RCC models were developed to compare the treatment efficacy in the International Metastatic RCC Database Consortium favorable-risk and intermediate- or poor-risk groups. JX-594 was systemically injected through the peritoneum, whereas sunitinib was orally administered. Post-treatment, tumor microenvironment (TME) remodeling was determined using immunofluorescence analysis. Systemic JX-594 monotherapy injection demonstrated therapeutic benefit in both early- and advanced-stage mRCC models. Sunitinib monotherapy significantly reduced the primary tumor burden and number of lung metastases in the early-stage, but not in the advanced-stage mRCC model. Systemic JX-594 delivery remodeled the primary TME and lung metastatic sites by increasing tumor-infiltrating CD4/8+ T cells and dendritic cells. Systemic JX-594 monotherapy demonstrated significantly better therapeutic outcomes compared with sunitinib monotherapy in both early- and advanced-stage mRCCs by converting cold tumors into hot tumors. Sunitinib monotherapy effectively suppressed primary tumor growth and lung metastasis in early-stage mRCC.

655: EBAG9/RCAS1 Expression Enhances Tumor Growth in Renal Cell Carcinoma

2005 ◽  
Vol 173 (4S) ◽  
pp. 178-179
Author(s):  
Tetsuo Ogushi ◽  
Takahashi Satoru ◽  
Takumi Takeuchi ◽  
Tetsuya Fujimura ◽  
Tomohiko Urano ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Tumor Growth ◽  
Cell Carcinoma ◽  
Renal Cell

Beyond Promoter: The Role of Macrophage in Invasion and Progression of Renal Cell Carcinoma

2020 ◽  
Vol 15 (7) ◽  
pp. 588-596
Author(s):  
Haibao Zhang ◽  
Guodong Zhu
Keyword(s):  
Renal Cell Carcinoma ◽  
Tumor Microenvironment ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Cell Formation ◽  
Biological Behavior ◽  
Tumor Stem Cell ◽  
The Past ◽  
The Common

Renal cell carcinoma (RCC) is one of the common urologic neoplasms, and its incidence has been increasing over the past several decades; however, its pathogenesis is still unknown up to now. Recent studies have found that in addition to tumor cells, other cells in the tumor microenvironment also affect the biological behavior of the tumor. Among them, macrophages exist in a large amount in tumor microenvironment, and they are generally considered to play a key role in promoting tumorigenesis. Therefore, we summarized the recent researches on macrophage in the invasiveness and progression of RCC in latest years, and we also introduced and discussed many studies about macrophage in RCC to promote angiogenesis by changing tumor microenvironment and inhibit immune response in order to activate tumor progression. Moreover, macrophage interactes with various cytokines to promote tumor proliferation, invasion and metastasis, and it also promotes tumor stem cell formation and induces drug resistance in the progression of RCC. The highlight of this review is to make a summary of the roles of macrophage in the invasion and progression of RCC; at the same time to raise some potential and possible targets for future RCC therapy.

Novel combination therapy with imiquimod and sorafenib for renal cell carcinoma

2014 ◽  
Vol 21 (7) ◽  
pp. 702-706 ◽  
Author(s):  
Takashi Karashima ◽  
Toshihiro Komatsu ◽  
Mayumi Niimura ◽  
Chiaki Kawada ◽  
Masayuki Kamada ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Combination Therapy ◽  
Cell Carcinoma ◽  
Renal Cell

scholarly journals ELR510444 Inhibits Tumor Growth and Angiogenesis by Abrogating HIF Activity and Disrupting Microtubules in Renal Cell Carcinoma

PLoS ONE ◽  
2012 ◽  
Vol 7 (1) ◽  
pp. e31120 ◽  
Author(s):  
Jennifer S. Carew ◽  
Juan A. Esquivel ◽  
Claudia M. Espitia ◽  
Christoph M. Schultes ◽  
Marcel Mülbaier ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Tumor Growth ◽  
Cell Carcinoma ◽  
Renal Cell

Lenvatinib in the management of metastatic renal cell carcinoma: a promising combination therapy?

2018 ◽  
Vol 14 (4) ◽  
pp. 461-467 ◽  
Author(s):  
Delia De Lisi ◽  
Ugo De Giorgi ◽  
Cristian Lolli ◽  
Giuseppe Schepisi ◽  
Vincenza Conteduca ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Combination Therapy ◽  
Cell Carcinoma ◽  
Metastatic Renal Cell Carcinoma ◽  
Renal Cell

scholarly journals TRPM7 Regulates AKT/FOXO1–Dependent Tumor Growth and Is an Independent Prognostic Indicator in Renal Cell Carcinoma

2018 ◽  
Vol 16 (6) ◽  
pp. 1013-1023 ◽  
Author(s):  
Zhijian Zhao ◽  
Mengping Zhang ◽  
Xiaolu Duan ◽  
Yiwen Chen ◽  
Ermao Li ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Tumor Growth ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Prognostic Indicator

Characterizing and Modulating the Tumor Microenvironment in Renal Cell Carcinoma: Potential Therapeutic Strategies

2012 ◽  
pp. 239-252
Author(s):  
Sumanta Kumar Pal ◽  
Karen Reckamp ◽  
Hua Yu ◽  
Robert A. Figlin ◽  
Robert A. Figlin ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Tumor Microenvironment ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Therapeutic Strategies
Sign in / Sign up

Export Citation Format

Share Document